← Leaderboards
Rachel A F Wozniak
University Of Rochester
$2,167,864
Attributed
$2,167,864
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $417.1K · FY2018–25$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,167,864 · 2
By mechanism
R01$1,205,289 · 1
K08$962,575 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Rochester
Same institution · by research overlap
- William H Merigan$11,100,062
- Jean-Philippe Y Couderc$7,749,612
- Hani A Awad$11,683,407
Others in their field
Other Emerging Leaders on “Severity Of Illness”
- Laura McNay · Leidos Biomedical Research, Inc.$15,147,252
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
- Vanessa Rivera-Amill · Ponce School Of Medicine$12,587,042
- Colin Masters · University Of Melbourne$10,651,748
- Barbara Halina Braffett · George Washington University$9,972,097
- Ionut Bebu · George Washington University$9,972,097
Research focus
Severity Of IllnessBiologicalLaboratoriesPathogenesisVisionBlindnessEye InfectionsKeratitisMediatingMouse ModelStaphylococcus AureusTissuesAntibioticsCellsCorneaDrug DiscoveryInfectionIn VivoAntibiotic ResistanceDesignAntimicrobialDevelopment PlansAdvanced SystemCoupled
Grant awards (8)
Virulence of Staphylococcus aureus Corneal Infections$394,083
R01 · FY2025 · EY · contact PI
Virulence of Staphylococcus aureus Corneal Infections$394,083
R01 · FY2024 · EY · contact PI
Virulence of Staphylococcus aureus Corneal Infections$417,123
R01 · FY2023 · EY · contact PI
Development of Novel Ophthalmic Antibiotics$148,959
K08 · FY2022 · EY · contact PI
Development of Novel Ophthalmic Antibiotics$203,404
K08 · FY2021 · EY · contact PI
Development of Novel Ophthalmic Antibiotics$203,404
K08 · FY2020 · EY · contact PI
Development of Novel Ophthalmic Antibiotics$203,404
K08 · FY2019 · EY · contact PI
Development of Novel Ophthalmic Antibiotics$203,404
K08 · FY2018 · EY · contact PI